Read More

Twist Bioscience Launches Multiplexed Gene Fragments, Pools Of Directly Synthesized Double-Stranded DNA Up To 500 Base Pairs In Length With No Limit On Sequence Number To Enable High Throughput Screening Applications

No limit to number of fragments included in the poolsOptimized chemistry enables direct synthesis of up to 500 bp double stranded fragmentsTwist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to

TWST

Read More

The Journal Of Clinical And Aesthetic Dermatology Published Arcutis Biotherapeutics’ Outcomes Of A Comprehensive Evaluation By An Expert Dermatologist Panel Assessing The Formulation Ingredients Of ZORYVE Topical Foam, 0.3%

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation

ARQT

Read More

Bristol Myers Squibb Shares Update On Phase 3 CheckMate -73L Trial; Says Trial Did Not Meet Its Primary Endpoint Of Progression-Free Survival In Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer

Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer

BMY